Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Sutro Biopharma, Inc.NASDAQ: STRO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $38.48M (cash outflow) fell 49.3% year over year, behind the -37.4% change in trailing-twelve-month net income. Sequentially, it fell 17.7% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.

Context

  • Net income amounted to 186.5% of revenue in FY2025, down 180.2 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$66.64M (-65.1%) for the fiscal year ending Dec 2026, a slowdown from the -16.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$38.48M-17.7% QoQ
Last fiscal yearDec 2025
-$191.09M-16.0% YoY
LTMMar 2026
-$153.6M-37.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.3%+216.4%+265.7 pp
1 year-16.0%-65.1%-49.1 pp
3-year CAGR+17.0%-26.5%-43.6 pp
5-year CAGR-23.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(191.09M) USD
Year-over-year change
+16.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.4% is the 7th highest of 8, against a peer median of +21.2%.
  • Net income amounts to 154.2% of revenue for STRO, versus a peer median of 45837.5%.
STRO Competitors
Net Income for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$153.6M USD-37.4%+17.0%154.2%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$113.22M USD-48.4%+6.6%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$108M USD+21.2%+44.8%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$87.07M USD+21.4%+12.6%—
CNTBConnect Biopharma Holdings LimitedFY2025$55.48M USD+255.0%-21.8%86687.5%
STTKShattuck Labs, Inc.LTM Mar 2026$49.87M USD-29.4%-21.8%4987.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$44.1M USD—+41.0%—
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.6M USD+98.3%-25.7%96.7%
IFRXInflaRx N.V.LTM Mar 2026€41.2M EUR-7.9%+14.1%140477.1%
Peer median (excluding STRO) —+21.2%+9.6%45837.5%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Depreciation & Amortization4.84M5.69M6.82M7.22M7.32M
Deferred Income Tax7.24M0000
Stock-Based Compensation23.24M26.3M24.91M24.69M14.01M
Change in Working Capital(17.62M)104.41M(34.38M)8.9M(50.4M)
Accounts Receivables(6.9M)5.34M(28.96M)27.46M4.64M
Inventory(4.55M)0000
Accounts Payables6.43M(1.23M)4.81M706K(2.47M)
Other Working Capital(12.61M)100.29M(10.23M)(19.27M)(52.57M)
Other Non-Cash Items6.16M(13.65M)(2.17M)(4.88M)42.92M
Operating Cash Flow(81.68M)3.55M(111.62M)(191.54M)(177.23M)
Capital Expenditures(15.32M)(7.86M)(4.32M)(3.1M)(1.7M)
Acquisitions (Net)028.74M000
Purchases of Investments(248.73M)(216.67M)(460.3M)(461.52M)(264.95M)
Sales of Investments166.73M189.5M460.69M683.13M311.66M
Other Investing Activities9K(28.73M)000
Investing Cash Flow(97.32M)(35.02M)(3.92M)218.51M45.01M
Debt Repayment0(9.38M)(12.5M)(4.08M)0
Common Stock Issued056.27M11.97M96.53M376K
Common Stock Repurchased(7K)0000
Dividends Paid00000
Other Financing Activities4.25M1.42M138.08M1.61M(332K)
Financing Cash Flow3.26M48.31M137.55M94.05M44K
Effect of Forex Changes00000
Net Change in Cash(175.74M)16.84M22.01M121.02M(132.17M)
Free Cash Flow(97M)(4.31M)(115.93M)(194.64M)(178.93M)

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.